Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

Tom2772 Aug. 20 at 9:05 AM

$OTLK $REGN $ABBV Outlook To Expand Ophthalmic Bevacizumab Empire With Pre-Filled Presentation Outlook Therapeutics is exploring a pre-filled syringe version of its ophthalmic bevacizumab Lytenava, while eyeing Latin America, Asia, and MENA for further deals. Outlook Therapeutics is developing a pre-filled syringe version of its ophthalmic bevacizumab treatment Lytenava for a Europe-first launch by end-2028 or early 2029. https://insights.citeline.com/generics-bulletin/products/value-added-medicines/outlook-to-expand-ophthalmic-bevacizumab-empire-with-pre-filled-presentation-A7ITQG5AMNG3BHDCSVHS5HF4EM/

0 · Reply

TeresaLey863 Aug. 20 at 7:27 AM

$V $JNJ $MA $INTC $ABBV Visa and Mastercard benefit from electronic-payment growth, Johnson & Johnson provides diversified healthcare exposure, Intel remains focused on semiconductor manufacturing and AI opportunities, and AbbVie benefits from its pharmaceutical portfolio. I'm watching payment volumes, healthcare demand, foundry execution, and prescription growth.

0 · Reply

TNNStockAnalysisNews Aug. 20 at 5:49 AM

Top Stock Gainers Today (August 19, 2026): $BULL — Gaining 8.95% to $8.64 $LLY — Up 5.18% to $1,280, First Pharma Company to $1 Trillion $ABBV — Trading Higher Alongside the Broader Healthcare Sector Rally $XLV $GOLD https://truthsandnews.com/markets/top-stock-gainers-today-august-19-2026-moderna-explodes

0 · Reply

55X_ROI_Q1_2026 Aug. 19 at 9:28 PM

$MRNA @EingeLTrade $SLS Phase 2 mOS of > 67.6 months for GPS AML Remission Maintenance was better than Transplant ... Phase 3 Registrational Results are Now imminent... Something very similar to what happened for $MRNA will be Happening for SLS - ANY DAY NOW. Gps has proven effective in preventing relapse and extending survival, 2x 3x 4x - in ALL Prior Trials Including 2 for AML Remission Maintenance. While BAT / Aza+VEN / for the Control Arm recently Failed 3 Large Phase 3 AML Trials Conducted by $ABBV - including Failing the VIALE-M Maintenance for First Remission Patients, and Failed the VIALE-T Post Transplant Maintenance trial.

0 · Reply

biolover Aug. 19 at 6:02 PM

$LLY $NVO $VKTX BL is bypassing novo , $ABBV and going head to head against Lilly 😂. What the hell is he seeing on efficacy from phase 3 ? > 4500 pts been on drug > 1 year I know tolerability is pristine

1 · Reply

GoforProMIS Aug. 19 at 4:17 PM

$PMN CEO Neil Warma attended and presented at Jefferies Healthcare, Oppenheimer CNS and at the Bio International Conference with the opportunity of 1to1 meetings. As the Alzheimer Conference took place on on 12-15 July the 4-6 week NDA analyses by the specialist of pharmaceutical companies should be done. IMO we have 5-12 pharmaceutical companies interested in PMN: Biogen /Eisai due to high Aria of Leqembi. Roche as they lost bn with Gantenerumab and need a solution. $ABBV $BMY $NVS are keen to get into neurology as partnership. Pfizer and Takeda looking for Episelect Platform!

0 · Reply

55X_ROI_Q1_2026 Aug. 19 at 3:15 PM

$SLS Yes/ Just sub in GPs and for AML --- recall $MRK Dr. Julie Cohen in Co-Authoring and Publishing the GPS Key Phase 2 Results, Recommended running a Phase 3 for GPS and Keytruda in Plat Resistant Ovarian Cancer. GPs Key Phase 2 MOS was BETTER (18.4 months) than the FDA Approved $IMGN Elahere (16.4 months) in the same exact Patient setting. $ABBV Bought IMGN for $10B based on this Data. And GPS is better.

0 · Reply

MissionControl Aug. 19 at 2:10 PM

$ABBV Great morning surprise. 👀

0 · Reply

HawkEye828 Aug. 19 at 1:39 PM

Go Merck...PROK will easily blow past 95% once Rilparencel is appoved for Chronic Kidney disease. $PROK Analysts Sentiment Buy Price Target 6.250 Upside +369.92% prokidney.com/clinical-stud.... Phase 2 with 70% response rate for kidney disease. Phase 3 on deck. Riprencel cell therapy designed to delay or completely prevent the need for dialysis which is one of the highest Medicare expenses ...at $30 Billion a year/ 90k to 100k per patient. $RHHBY, $NVO, $LLY, $ABBV

1 · Reply

AXLFI_HQ Aug. 19 at 12:24 PM

$ABBV Companies are using acquisitions, divestitures, separations, and business combinations to gain scale, improve focus, unlock value, and optimize capital allocation. Learn more: https://axlfi.com/themes/379

0 · Reply

AbbVie price target raised to $303 from $298 at Piper Sandler

Aug 18, 2026, 8:00 AM EDT - 2 days ago

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

2026-08-17T10:55:57.000Z - 3 days ago

AbbVie price target raised to $300 from $295 at Wells Fargo

2026-08-17T08:29:38.000Z - 3 days ago

AbbVie upgraded to Outperform from Peer Perform at Wolfe Research

Aug 13, 2026, 11:15 PM EDT - 6 days ago

Expert explains why healthcare is a top-performing sector

AMGN BIIB GILD JNJ LLY MRK UNH

2026-08-10T12:16:02.000Z - 10 days ago

AbbVie price target raised to $260 from $246 at Evercore ISI

2026-08-05T14:36:14.000Z - 14 days ago

AbbVie upgraded to Buy from Hold at Erste Group

2026-08-04T13:35:25.000Z - 15 days ago

AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA

2026-08-04T12:10:59.000Z - 16 days ago

AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic

Aug 4, 2026, 8:00 AM EDT - 16 days ago

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

2026-08-04T10:52:04.000Z - 16 days ago

AbbVie price target raised to $288 from $261 at Guggenheim

2026-08-03T12:42:03.000Z - 16 days ago

AbbVie price target raised to $285 from $265 at Cantor Fitzgerald

2026-08-03T12:06:31.000Z - 17 days ago

AbbVie price target raised to $296 from $278 at Morgan Stanley

2026-08-03T11:06:04.000Z - 17 days ago

AbbVie price target raised to $290 from $282 at Canaccord

2026-07-31T14:01:14.000Z - 19 days ago

AbbVie says ‘quite pleased’ with Skyrizi momentum

2026-07-31T13:31:24.000Z - 19 days ago

AbbVie raises FY26 revenue view to about $67.6B from about $67.3B

2026-07-31T13:30:48.000Z - 19 days ago

AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84

2026-07-31T13:30:35.000Z - 19 days ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

2026-07-31T13:16:13.000Z - 19 days ago

AbbVie says continues to make ‘excellent progress’ advancing pipeline

Jul 31, 2026, 9:00 AM EDT - 19 days ago

AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 19 days ago

AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 19 days ago

AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 8:36 AM EDT - 19 days ago

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

Jul 31, 2026, 8:31 AM EDT - 19 days ago

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

2026-07-31T11:51:57.000Z - 20 days ago

AbbVie reports Q2 adjusted EPS $3.65, consensus $3.61

Jul 31, 2026, 7:50 AM EDT - 20 days ago

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

Jul 31, 2026, 7:47 AM EDT - 20 days ago

AbbVie Reports Second-Quarter 2026 Financial Results

Jul 30, 2026, 8:00 AM EDT - 21 days ago

JUVÉDERM® Day Returns to U.S. on August 19

Jul 29, 2026, 3:00 AM EDT - 22 days ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jul 29, 2026, 3:00 AM EDT - 22 days ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

$Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$

Jul 23, 2026, 4:00 PM EDT - 27 days ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GMAB

Jul 17, 2026, 8:00 AM EDT - 4 weeks ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jul 14, 2026, 8:05 AM EDT - 5 weeks ago

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Jul 13, 2026, 5:06 PM EDT - 5 weeks ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

APGE SBIO

Jul 7, 2026, 11:45 AM EDT - 6 weeks ago

Buy these quality, low-stress stocks for the summer, says Jefferies

AXP HD LOW MCD NFLX PEP PG

$AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma$

Jul 6, 2026, 1:45 PM EDT - 6 weeks ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Jun 30, 2026, 6:02 AM EDT - 7 weeks ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

$AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma$

Jun 29, 2026, 4:15 PM EDT - 7 weeks ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 29, 2026, 3:10 AM EDT - 7 weeks ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:00 AM EDT - 7 weeks ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 26, 2026, 4:50 PM EDT - 7 weeks ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 2:39 PM EDT - 7 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

Jun 26, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

APGE

Jun 24, 2026, 8:00 AM EDT - 2 months ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 23, 2026, 8:00 AM EDT - 2 months ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 5:00 AM EDT - 2 months ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 3:00 AM EDT - 2 months ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 22, 2026, 10:30 AM EDT - 2 months ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Press release: M&A announcement

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Jun 22, 2026, 7:06 AM EDT - 2 months ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

Jun 22, 2026, 7:00 AM EDT - 2 months ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

Jun 20, 2026, 12:11 PM EDT - 2 months ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

Jun 19, 2026, 11:17 AM EDT - 2 months ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

Jun 18, 2026, 4:05 PM EDT - 2 months ago

AbbVie Declares Quarterly Dividend

Jun 16, 2026, 8:00 AM EDT - 2 months ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 12, 2026, 3:00 AM EDT - 2 months ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 10, 2026, 11:47 AM EDT - 2 months ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 9, 2026, 10:40 AM EDT - 2 months ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 2 months ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 3, 2026, 7:04 PM EDT - 2 months ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 3:30 AM EDT - 2 months ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

Jun 2, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 29, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 27, 2026, 6:18 PM EDT - 3 months ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 3:33 PM EDT - 3 months ago

US FDA approves AbbVie's rare blood cancer drug

May 22, 2026, 8:00 AM EDT - 3 months ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

Tom2772 Aug. 20 at 9:05 AM

0 · Reply

TeresaLey863 Aug. 20 at 7:27 AM

0 · Reply

TNNStockAnalysisNews Aug. 20 at 5:49 AM

0 · Reply

55X_ROI_Q1_2026 Aug. 19 at 9:28 PM

0 · Reply

biolover Aug. 19 at 6:02 PM

1 · Reply

GoforProMIS Aug. 19 at 4:17 PM

0 · Reply

55X_ROI_Q1_2026 Aug. 19 at 3:15 PM

0 · Reply

MissionControl Aug. 19 at 2:10 PM

$ABBV Great morning surprise. 👀

0 · Reply

HawkEye828 Aug. 19 at 1:39 PM

1 · Reply

AXLFI_HQ Aug. 19 at 12:24 PM

0 · Reply

TMC101 Aug. 19 at 10:20 AM

$ABBV 🤔

0 · Reply

KarinSparrow145 Aug. 19 at 9:08 AM

$GENI $ABBV $SBET $DAL Genius Sports benefits from sports-data and betting partnerships, AbbVie benefits from diversified pharmaceutical demand, SBET remains highly speculative, and Delta benefits from travel demand and premium-airline activity. I'm watching contract growth, drug sales, funding, passenger demand, and margins.

0 · Reply

CDSTrading Aug. 19 at 8:57 AM

0 · Reply

TeenageMutantNinjaTrader Aug. 19 at 4:09 AM

$ABBV here we are again

0 · Reply

55X_ROI_Q1_2026 Aug. 19 at 3:49 AM

$SLS $XBI $GLSI IDMC Unblinded Actual Phase 3 MOS and Immune Response Data from the Interim Analysis on Jan 23rd ... Volume jumped from 1m'ish daily to 28M. Share Price Climbed 60% the Day Jan 28th, SLS did a RDO / $25M Cash Raise + warrants and still the Share Price / with all the Extra Shares was up 50% --- SMART MONEY - Knew Immediately Gps Was Golden ALL Pooled Survival Data Immune Response Rates --- told all the AML Industry Players. Smart Money was loading in - hand over Fist. / / When the 80th Event is ANNOUNCED -- The share Price will launch. SMART MONEY Knows what most the Inch thick mile wide retail do not. PS Since then: BAT FAILED 3 Large Phase 3 AML Trials Conducted by $ABBV including 2 for AML Remission / Transplant Maintenance.

0 · Reply

JCJustCharting Aug. 18 at 10:12 PM

$ABBV did you guy take anything with me ?https://x.com/JC_JustCharts/status/2089817358919503922?s=20

0 · Reply

WallStJesus Aug. 18 at 9:25 PM

$ABBV -

0 · Reply

l4ndsh4rk Aug. 18 at 7:58 PM

$ABBV Abbie V

0 · Reply

TMC101 Aug. 18 at 3:54 PM

$ABBV Are you bullish on any stock?🤔

1 · Reply

HydrogenH2 Aug. 18 at 3:15 PM

$JNJ $ABBV I'm taking profits !! Thanks !!

0 · Reply

55X_ROI_Q1_2026 Aug. 18 at 3:04 PM

$SLS a fine point. and to underscore - $ABBV Statistical Analysis Plan (SAP) for VIALE-M - Phase 3 AML Remission Maintenance Trial - dropped the Efficacy Readout in V5.0 --- after attempting 8 Different Dosing Regimes, they quietly terminated the Trial. -- i've said this before - this trial VIALE-M / and VIALE-T were the most Serious Threats to SLS Share Holders -- if M & T were successful, it would have meant a new Higher Bar for Gps to Hurdle. --- instead, just more Toxicity and extremely poor survival.

0 · Reply

JCJustCharting Aug. 18 at 1:53 PM

$ABBV next time You should just be in my group https://x.com/jc_justcharts/status/2089712169419972938?s=46

0 · Reply

Market Cap	457.46B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	23.03
Forward PE	17.80
Profit Margin	6.91%
Debt to Equity Ratio	-12.03

Volume	5,535,900
Avg Vol	6,956,894
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	96%
Beta	0.30
Analysts	Strong Sell
Price Target	$275.77